Evergreening, patent challenges, and effective market life in pharmaceuticals

C. Scott Hemphill and Bhaven Sampat

Journal of Health Economics, 2012, vol. 31, issue 2, 327-339

Abstract: Observers worry that generic patent challenges are on the rise and reduce the effective market life of drugs. A related concern is that challenges disproportionately target high-sales drugs, reducing market life for these “blockbusters.”

Keywords: Pharmaceuticals; Patents; Innovation; Hatch–Waxman (search for similar items in EconPapers)
JEL-codes: I18 K20 O31 O34 (search for similar items in EconPapers)
Date: 2012
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (48)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0167629612000057
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:jhecon:v:31:y:2012:i:2:p:327-339

DOI: 10.1016/j.jhealeco.2012.01.004

Access Statistics for this article

Journal of Health Economics is currently edited by J. P. Newhouse, A. J. Culyer, R. Frank, K. Claxton and T. McGuire

More articles in Journal of Health Economics from Elsevier
Bibliographic data for series maintained by Catherine Liu ().